ReViral Announces Publication of Article in Journal of Medicinal Chemistry ‘Perspectives’ Nov 14, 2018 by ReViral Ltd Read More
Positive results achieved in ReViral’s Phase IIa RSV challenge study Feb 5, 2018 by ReViral Ltd Read More
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus Sep 5, 2017 by ReViral Ltd Read More
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers Apr 24, 2017 by ReViral Ltd Read More
